nivolumab,ipilimumab
bms
['nsclc', 'check,mate,9la', '9la', 'sclc', 'lcsm,(-blcsm)', 'bms', 'scienceatbms']
at #asco23 will be presenting 4-year data from checkmate 9la for first-line combination dual immunotherapy + chemo versus chemo alone in patients with mnsclc with outcomes by tumor histologic subtype. #lcsm 
Official Bristol Myers Squibb Twitter handle for science. Connecting researchers, scientists and healthcare professionals through science; guidelines below: